FGFR3 is one of the most common genetic alterations, and FGFR-targeted therapy has become a promising treatment strategy in BC; FGFR1-4 alterations in UC patients respond well to FGFR inhibitors such as erdafitinib and rogaratinib, and similar therapeutic results have been achieved targeting the PI3K pathway [17,18]. The gene discussed is PIK3CA; the disease is breast cancer.